Overview
Compare with BLUE BIOFUELS, INC., Clean Vision Corp or GREENWAY TECHNOLOGIES, INC. & SUBSIDIARIES, or pick any stock.
- TickerQGAI on OTC1
- IndustryIndustrial Organic Chemicals1
- HeadquartersSan Diego, California1
- Incorporated inNV3
- Business address15656 Bernardo Center Drive, #801, San Diego, Ca 921273
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
See how the biggest companies compare on our leaderboards
Quantumzyme Corp., is a biotransformation company, focused on clean and green chemistry. Specifically, Quantumzyme is in the business of developing engineered enzymes in the application of active pharmaceutical ingredients (“API”) production. As we move forward, we intend to expand beyond the API marketplace and engineer enzymes for the use and deployment in other business sectors such as fragrance and flavors, climate impacting applications like sustainable materials, plastic degradation and carbon capture. In the development and engineering of enzymes, we conduct research to enhance enzyme activity, selectivity, and specificity by applying novel quantum mechanics, molecular modelling, and engineering approaches. Our goal is to help to foster a clean, healthy, and well protected environment supporting a sustainable society and economy. Ultimately, we want to fulfil our vision by develop…4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-07-31 | 2024-07-31 |
|---|---|---|
| Sales | $0 | $0 |
| General and administrative | $18.1K | $31.7K |
| Professional fees | $162.4K | $131.9K |
| Total operating expenses | $180.5K | $163.6K |
| Loss from operations | -$180.5K | -$163.6K |
| Gain on extinguishment of debt | $2.5K | $0 |
| Interest expense | -$21.2K | -$15.0K |
| Total other expenses | -$18.7K | -$15.0K |
| Net loss before tax provision | -$199.3K | -$178.6K |
| Tax provision | $0 | $0 |
| Net loss | -$199.3K | -$178.6K |
| Net loss per common share: basic and diluted | -$0.01 | -$0.01 |
| Weighted average common shares outstanding - basic and diluted | 35.1M shares | 34.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2023-02-28 |
|---|---|---|---|---|
| Cash | $584 | $0 | $0 | |
| Prepaid expenses | $0 | $10.0K | ||
| Total current assets | $584 | $10.0K | ||
| Total assets | $584 | $10.0K | ||
| Accounts payable and accrued expenses | $175.2K | $109.8K | ||
| Due to related parties | $17.0K | $15.9K | ||
| Notes payable | $249.1K | $167.7K | ||
| Total current liabilities | $441.3K | $293.3K | ||
| Total liabilities | $441.3K | $293.3K | ||
| Commitments and Contingencies (See note 7) | $0 | $0 | ||
| Preferred stock value | $0 | $0 | ||
| Common Shares 750,000,000 authorized shares, par value $0.00001; 38,962,050 and 34,777,050 shares issued and outstanding as of July 31, 2025 and 2024 , respectively | $389 | $347 | ||
| Additional paid-in capital | $5.2M | $5.2M | ||
| Accumulated deficit | -$5.6M | -$5.4M | ||
| Total stockholders' deficit | -$440.7K | -$283.3K | -$104.7K | |
| Total liabilities and stockholders' deficit | $584 | $10.0K | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | 75.0M shares | |
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares issued | 39.0M shares | 34.8M shares | ||
| Common stock, shares outstanding | 39.0M shares | 34.8M shares | ||
| Preferred stock, shares authorized | 130.0M shares | 130.0M shares | 150.0M shares | |
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares |
| Period ending | 2025-07-31 | 2024-07-31 | 2023-07-31 | 2023-02-28 |
|---|---|---|---|---|
| Cash | $584 | $0 | $0 | |
| Prepaid expenses | $0 | $10.0K | ||
| Total current assets | $584 | $10.0K | ||
| Total assets | $584 | $10.0K | ||
| Accounts payable and accrued expenses | $175.2K | $109.8K | ||
| Due to related parties | $17.0K | $15.9K | ||
| Notes payable | $249.1K | $167.7K | ||
| Total current liabilities | $441.3K | $293.3K | ||
| Total liabilities | $441.3K | $293.3K | ||
| Commitments and Contingencies (See note 7) | $0 | $0 | ||
| Preferred stock value | $0 | $0 | ||
| Common Shares 750,000,000 authorized shares, par value $0.00001; 38,962,050 and 34,777,050 shares issued and outstanding as of July 31, 2025 and 2024 , respectively | $389 | $347 | ||
| Additional paid-in capital | $5.2M | $5.2M | ||
| Accumulated deficit | -$5.6M | -$5.4M | ||
| Total stockholders' deficit | -$440.7K | -$283.3K | -$104.7K | |
| Total liabilities and stockholders' deficit | $584 | $10.0K | ||
| Common stock, shares authorized | 750.0M shares | 750.0M shares | 75.0M shares | |
| Common stock, par value | $0.00 | $0.00 | $0.00 | |
| Common stock, shares issued | 39.0M shares | 34.8M shares | ||
| Common stock, shares outstanding | 39.0M shares | 34.8M shares | ||
| Preferred stock, shares authorized | 130.0M shares | 130.0M shares | 150.0M shares | |
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2025-07-31 | 2024-07-31 |
|---|---|---|
| Net loss | -$199.3K | -$178.6K |
| Gain on extinguishment of debt | -$2.5K | $0 |
| Prepaid expenses | $10.0K | -$10.0K |
| Accounts payable | $65.4K | $81.0K |
| Due to related party | $1.1K | $5.9K |
| Net cash from operating activities | -$125.2K | -$101.6K |
| Proceeds from the issuance of common stock | $41.9K | $0 |
| Proceeds from notes payable | $83.9K | $101.6K |
| Net cash from financing activities | $125.8K | $101.6K |
| Net increase in cash | $584 | $0 |
| Cash paid for interest | $0 | $0 |
| Cash paid for taxes | $0 | $0 |
| Share to be issued for settlement of notes payable | $0 | $3.2K |
No quarter-by-quarter statement was filed.
What it owns
What Quantum Genesis AI Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Properties, in its own words
Our office is located in a shared office space which presently is sufficient for our needs, and we pay approximately $500.00 a month, which we believe will suffice for our immediate needs. Management does not anticipate any issue in locating and securing additional office space as we implement our plan of operation and the business grows.
Item 2 of the 10-K filed Nov 13, 2025.4
Former names
Timeline
Filings
39 filings to the SEC since October 2021: 3 annual reports, 6 quarterly reports, 3 major events, 27 other. The latest 20:
- Oct 8, 20261-A EDGAR
- Jun 11, 202610-Q EDGAR
- Apr 15, 202610-Q/A EDGAR
- Apr 15, 202610-Q/A EDGAR
- Apr 15, 202610-K/A EDGAR
- Apr 15, 20268-K EDGAR
- Mar 19, 202610-Q EDGAR
- Mar 17, 2026NT 10-Q EDGAR
- Feb 13, 20268-K EDGAR
- Jan 15, 2026DEF 14C EDGAR
- Jan 7, 20268-K EDGAR
- Dec 15, 202510-Q EDGAR
- Nov 17, 202510-K/A EDGAR
- Nov 13, 202510-K EDGAR
- Oct 28, 2025NT 10-K EDGAR
- Jun 20, 202510-Q EDGAR
- Jun 16, 2025NT 10-Q EDGAR
- Apr 15, 2025UPLOAD EDGAR
- Apr 1, 2025CORRESP EDGAR
- Apr 1, 202510-12G/A EDGAR
The 39 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How Quantum Genesis AI Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARQuantum Genesis AI Corp.1
- CIK0001663038
- Employer ID (EIN)36-48064811
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inNevada4
- Fiscal year endsJuly 311
- Industry code (SIC)2860 Industrial Organic Chemicals1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address15656 Bernardo Center Drive, #801, San Diego, CA 921271
- Phone858-216-76761
- Shares outstanding40,972,050 as of Jun 11, 20268
- Public float$4.3M as of Jan 31, 20254
- AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceJan 11, 20161
- Filings75 in all: UPLOAD (13), 10-Q (10), 8-K (8), S-1/A (7), CORRESP (6), NT 10-Q (4), 1-A/A (3), 10-K (3)1
All 24 form types
1-A (2), 10-12G/A (2), 10-K/A (2), 10-Q/A (2), NT 10-K (2), 10-12G (1), 15-15D (1), C (1), C-AR (1), C-TR (1), C-W (1), C/A (1), DEF 14C (1), EFFECT (1), QUALIF (1), S-1 (1)
- Latest filingsAnnual report (10-K) Nov 13, 2025
Quarterly report (10-Q) Jun 11, 2026
Latest 8-K (8-K) Apr 15, 2026
Risk factors and legal proceedings
The risks Quantum Genesis AI Corp. names in Item 1A of its 10-K filed Nov 13, 2025: 25 risks under these headings, as written.4
- Financial Projections.
- We may fail to establish and maintain strategic relationships.
- If we were to lose the services of Mr. Kulkarni, we may not be able to execute our business strategy.
- If we are unable to hire qualified personnel and retain or motivate key personnel, we may not be able to grow effectively.
- Our Limited Workforce May Hinder Our Ability to Execute Our Business Objectives
- A decline in general economic conditions could have a material adverse effect on our business, financial condition, and results of operations.
- Our sole officer and director have little experience managing a public company.
- We may need additional capital in the future in order to expand our business.
- With respect to customers purchasing our products for the manufacture of active pharmaceutical ingredients (“API”) for which they have exclusivity due to patent protection, the termination or expiration of such patent protection and any resulting generic competition may materially and adversely affect our revenues, financial condition, or results of operations.
- We are dependent on a limited number of contract manufacturers for large scale production of substantially all of our enzymes.
- The Lack of Formal Agreements for Off-Site Testing Facilities May Disrupt Our Operations and Increase Costs
- Competitors and potential competitors who have greater resources and experience than we do may develop products and technologies that make ours obsolete or may use their greater resources to gain market share at our expense.
The other 13 risks
- Ethical, legal, and social concerns about genetically engineered products and processes could limit or prevent the use of our technology, products and processes and limit our revenues.
- Our efforts to prosecute, maintain, protect and/or defend our intellectual property rights may not be successful.
- Third parties may claim that we are infringing, violating, or misappropriating their intellectual property rights, which may subject us to costly and time-consuming litigation and prevent us from developing or commercializing our technology, products, or services.
- Our investors may lose their entire investment because our financial status creates a doubt whether we will continue as a going concern.
- We may not be able to enforce our intellectual property rights throughout the world.
- Confidentiality and non-use agreements with employees, consultants, advisors and other third parties may not adequately prevent disclosures and non-use of trade secrets and other proprietary information.
- We expect our quarterly financial results to fluctuate.
- Dual-Class Capital Structure Limits the Ability of Other Shareholders to Influence Corporate Decisions
- Concentrated Voting Power May Result in Decisions That Do Not Align with Minority Shareholders’ Interests
- Risk of Unexpected Conversion or Dilution of Voting Power
- Our Shares are “Penny Stock,” which impairs trading liquidity.
- As an “Emerging Growth Company” any decision to comply with the reduced disclosure requirements applicable to emerging growth companies could make our Shares less attractive to investors.
- We May Continue to Take Advantage of Reduced Reporting Requirements Even If We No Longer Qualify as an Emerging Growth Company
- Our status as an “Emerging Growth Company” under the JOBS Act of 2012 may make it more difficult to raise capital.
Legal proceedings
The Company may, from time to time, be involved in various legal proceedings incidental to the conduct of our business. Historically, the outcome of all such legal proceedings has not, in the aggregate, had a material adverse effect on our business, financial condition, results of operations or liquidity. There are no material pending or threatened legal proceedings at this time.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARBylaws or fiscal year changed
- 11SEC EDGARBylaws or fiscal year changed